Mar. 16 at 8:09 PM
$NAGE The Boston General (Brigham Women's) Long COVID trial had less than conclusive results. In order to bolster my hopes for the norwegoan trial, I did an AI search to better understand the Boston trial: "A randomized, double-blind, placebo-controlled trial at Brigham and Women’s Hospital (and Mass General) found that high-dose nicotinamide riboside (NR) safely increased NAD+ levels but did not significantly improve primary cognitive or secondary symptom outcomes compared to a placebo.
The study, published in The Lancet’s eClinicalMedicine in late 2025, evaluated 58 participants with long COVID symptoms such as "brain fog," fatigue, and sleep disturbances.
Key Findings
No Significant Group Difference: There were no statistically significant differences between the NR and placebo groups for the primary endpoint of cognition (memory and thinking scores) or secondary symptoms like fatigue, anxiety...continued
